Nolato AB (publ) NOLA-B.ST
Nasdaq Stockholm · Healthcare · Medical Devices
50.90 SEK
−1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Nolato
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 10,774 | 9,546 | 9,664 | 9,462 |
| EBITDA | 1,475 | 1,269 | 1,512 | 1,596 |
| Net income | 697 | 435 | 658 | 777 |
| Balance sheet | ||||
| Equity | 5,392 | 5,171 | 5,738 | 5,532 |
| Total debt | 1,934 | 1,870 | 1,527 | 1,454 |
| Cash | 1,011 | 688 | 672 | 482 |
| Net debt | 923 | 1,182 | 855 | 972 |
| Ratios and per share | ||||
| EBITDA margin | 13.7% | 13.3% | 15.6% | 16.9% |
| Profit margin | 6.5% | 4.6% | 6.8% | 8.2% |
| Return on equity | 12.9% | 8.4% | 11.5% | 14.0% |
| Earnings/share (SEK) | 2.59 | 1.61 | 2.44 | 2.88 |
| Book value/share (SEK) | 20.02 | 19.20 | 21.30 | 20.54 |
| Shares outstanding (M) | 269 | 269 | 269 | 269 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 17.6 |
| P/B | 2.5 |
| EV / EBITDA | 9.2 |
| Net debt / EBITDA | 0.6 |
| Return on equity | 14.1% |
| Profit margin | 8.2% |
| Beta 1Y | 0.99 |
| Revenue growth 1Y | −2.1% |
| Revenue CAGR 3Y | −4.2% |
| Earnings/share CAGR 3Y | +3.7% |
| ROE avg. 3Y | 11.3% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 1.70 |
| 2025 | 1.50 |
| 2024 | 1.50 |
| 2023 | 1.90 |
| 2022 | 1.90 |
Not investment advice. Figures may contain errors from the data source.